MUC1-MBP vaccine

The **MUC1-MBP vaccine** is a recombinant fusion protein vaccine comprised of the **human mucin 1 (MUC1) core peptide** and the **Escherichia coli maltose-binding protein (MBP)**, intended as a therapeutic cancer vaccine. MUC1 is an oncogenic glycoprotein overexpressed and aberrantly glycosylated in many human carcinomas, making it a validated tumor-associated antigen. MBP is used as a carrier or chaperone to enhance immunogenicity and facilitate protein expression and purification. Preclinical studies have shown that immunization with MUC1-MBP, sometimes in combination with BCG (Bacillus Calmette-Guérin) or anti-PD-1 antibody, induces vigorous **Th1 cellular and humoral immune responses**, **cytotoxic T-lymphocyte activity**, and **natural killer (NK) cell activation** against MUC1-positive tumors. The vaccine is being investigated as a candidate for immunotherapy of cancers such as **melanoma** and lung carcinoma, with demonstrated efficacy in mouse models and ongoing preclinical safety/toxicity studies. The approach leverages enhanced antigen presentation and immune activation against MUC1-expressing tumor cells[1][2][3][4].

Other names

MUC1-MBP fusion protein vaccineMUC-1-MBP fusion protein vaccineMUC 1-MBP fusion protein vaccine